Ayahuasca: Traditional Preparation, Research and Safety
What ayahuasca is as a traditional Amazonian preparation, what research and surveys show, why it can interact dangerously with other medicines, and how it differs from DMT.
Content last updated . This page has not been medically reviewed.
Safety first. Ayahuasca contains plant compounds that block an enzyme called monoamine oxidase (MAO). A 2026 case report describes a man who developed severe serotonin syndrome and needed a breathing tube and intensive care after taking ayahuasca and then over-the-counter dextromethorphan and diphenhydramine. He recovered. [1] Serotonin syndrome is a dangerous build-up of serotonin activity; NIDA says it is usually mild but can be life-threatening in rare cases. [2] If someone feels very unwell after taking ayahuasca, call 911 (US) or local emergency services; US Poison Help is 1-800-222-1222 (poison help by country). Never stop or change a prescribed medicine on your own; talk with the prescriber (talking with a health professional).
This page is information only. It does not describe how ayahuasca is made, how much is taken, or how ceremonies are run, and it does not recommend its use.
What ayahuasca is
Ayahuasca is a traditional brew used for therapeutic and ritual purposes by Indigenous groups of northwestern Amazonian countries such as Brazil, Peru, Colombia and Ecuador. It is made from a vine and a leafy plant: the vine Banisteriopsis caapi supplies beta-carboline compounds such as harmine, and the leaves of the shrub Psychotria viridis supply dimethyltryptamine (DMT). [3] A third plant, Diplopterys cabrerana, is also named as a DMT source in the medical literature. [1] The brew is not a single chemical. It is a preparation made from plants, which differs from DMT on its own; see DMT vs ayahuasca and traditional preparations vs isolated compounds.Why the two plants matter together
A pharmacokinetic modeling study explains that harmine blocks the MAO-A enzyme that would otherwise break DMT down quickly after it is swallowed, which allows more DMT to reach the brain. [4] That is also why the interaction risk above exists. It is a computer model built from rat and human data, not a clinical test. Reviews also note that brews made with substitute plants or with extracted or lab-made compounds (sometimes called "anahuasca" or "pharmahuasca") are a different thing from the traditional preparation. [5][6] Plant profiles: ayahuasca vine and chacruna.Traditional and religious contexts
Ayahuasca was originally used by Indigenous shamans for spirit communication and healing, and several Brazilian churches use it as a sacrament. [7] Members of one of them, the Santo Daime, consider it a medicinal sacrament. [8] Each tradition has its own meaning and rules, which belong to its people and are not reproduced here. Indigenous authors and scholars have raised concerns about outside demand, patenting and the medicalization of ayahuasca without respect for Indigenous rights and the sustainability of the plants. [9][10] See Indigenous traditions, ethics and conservation.What research shows
Evidence labels used here: promising but limited (some controlled data, small or short) and insufficient evidence (not enough to judge). Observational surveys cannot show cause and effect.| Question | What was studied | Finding and limits |
|---|---|---|
| Treatment-resistant depression | Randomized, double-blind, placebo-controlled trial, 29 patients, a single dose of ayahuasca or placebo, with scores checked 1, 2 and 7 days later [11] | Depression scores were lower than with placebo at all time points; response at day 7 was 64% vs 27%. Remission only trended toward significance. Follow-up was one week. Promising but limited. |
| Overall picture | A 2024 review [3] | Studies suggest good safety and tolerability, but there are few controlled studies, with small samples, single doses and short follow-up. |
| Post-traumatic stress, substance use | Same review [3] | Interest exists; benefit is not established. Insufficient evidence. |
| Brain imaging | Systematic review of imaging studies of LSD, psilocybin and ayahuasca [12] | Acute disruption of a resting brain network was consistent, but the review says it is unclear how central that network is to therapeutic potential. A brain finding is not a treatment outcome. |
Risks and who should be most careful
- Medicine interactions. Serotonin-affecting medicines and some over-the-counter products can combine dangerously with ayahuasca. A critical review of reported severe cases concluded that previous heart and liver disease and current use of serotonin-affecting medicines look like contraindications. [6] See interactions by drug class and psychedelic drug interactions.
- Common side effects. In the Global Ayahuasca Survey (an online, self-selected survey of 10,836 people in more than 50 countries), 69.9% reported acute physical effects, mainly vomiting, and 2.3% needed later medical attention. [13]
- Mental health effects. In the same survey 55.9% reported adverse mental health effects in the following weeks or months, though about 88% saw them as part of a positive process, and about 12% sought professional support. They were linked to anxiety disorders and to the strength of the spiritual experience. [13]
- Unsupervised use. Physical adverse effects in that survey were linked to taking ayahuasca in a non-supervised context. [13]
- Heart disease. A cardiovascular review says data are lacking for people with cardiovascular disease. [14]
- Psychosis or bipolar disorder. Clinical research excludes these groups as a precaution. [2]
- Pregnancy. Proper evidence not found for ayahuasca specifically; NIDA says effects of psychedelics in pregnancy are not well understood. [2]
Quality and labeling
Proper evidence not found from a regulator on the contents of ayahuasca offered outside research. One Uruguayan study analyzed samples from two groups and found a typical alkaloid composition and no adulterants, but it covers only those samples. [15] Do not generalize one sample to others. See evaluating retreat claims.Legal status
This is not legal advice, and laws change. In the United States, federal Schedule I (21 CFR 1308.11) lists dimethyltryptamine; the section text does not name ayahuasca or Banisteriopsis caapi, and how other US law treats the brew was not verified (US eCFR, read 2026-10-22). [16] A 2012 review describes how Brazil moved from prohibition to a 2010 national resolution setting rules for religious and ritual use. [17] We did not read Brazilian law itself, so that is background, not a statement of current law. Other countries: not verified. See psychedelic legal status by country.Frequently asked questions
Is ayahuasca the same as DMT?
No. DMT is one compound in the brew. The preparation also contains other plant compounds, including MAO-blocking beta-carbolines such as harmine. [3][4]
Why is ayahuasca risky with antidepressants and cold medicines?
Its MAO-blocking compounds can predispose people to serotonin toxicity when combined with other serotonin-affecting agents, as a 2026 case report shows. [1]
Does ayahuasca treat depression?
One small randomized trial of 29 people with treatment-resistant depression found a benefit over placebo after a single dose, with one week of follow-up. Larger and longer trials are needed. [11][3]
Is ayahuasca addictive?
Proper evidence not found in the sources read for ayahuasca itself. NIDA notes that a small laboratory study suggested psilocybin, DMT and mescaline are weakly reinforcing. [2]
Is ayahuasca legal?
It depends on the country and state, and on the activity. See the legal section above and the legal status guide.
References
- Pack S et al., Cureus 2026, Severe Serotonin Syndrome With Acute Respiratory Failure Following Ayahuasca and Dextromethorphan Use: A Case Report. Read 2026-10-22.
- National Institute on Drug Abuse, Psychedelic and Dissociative Drugs. Read 2026-10-22.
- Dos Santos RG et al., CNS Spectr 2024, Ayahuasca: pharmacology, safety, and therapeutic effects. Read 2026-10-22.
- Wittayakarn N et al., Toxicol Sci 2025, Development of a physiologically based pharmacokinetic model of N,N-dimethyltryptamine, harmine, and their interactions from ayahuasca in rats and humans. Read 2026-10-22.
- Brierley DI et al., Prog Neuropsychopharmacol Biol Psychiatry 2012, Developments in harmine pharmacology--implications for ayahuasca use and drug-dependence treatment. Read 2026-10-22.
- dos Santos RG et al., J Psychoactive Drugs 2013, A critical evaluation of reports associating ayahuasca with life-threatening adverse reactions. Read 2026-10-22.
- Hamill J et al., Curr Neuropharmacol 2019, Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness. Read 2026-10-22.
- Blainey MG et al., J Relig Health 2015, Forbidden therapies: Santo Daime, ayahuasca, and the prohibition of entheogens in Western society. Read 2026-10-22.
- Schenberg EE et al., Transcult Psychiatry 2022, Overcoming epistemic injustices in the biomedical study of ayahuasca: Towards ethical and sustainable regulation. Read 2026-10-22.
- Celidwen Y et al., Lancet Reg Health Am 2023, Ethical principles of traditional Indigenous medicine to guide western psychedelic research and practice. Read 2026-10-22.
- Palhano-Fontes F et al., Psychol Med 2019, Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Read 2026-10-22.
- Gattuso JJ et al., Int J Neuropsychopharmacol 2023, Default Mode Network Modulation by Psychedelics: A Systematic Review. Read 2026-10-22.
- Bouso JC et al., PLOS Glob Public Health 2022, Adverse effects of ayahuasca: Results from the Global Ayahuasca Survey. Read 2026-10-22.
- Wsół A et al., Pharmacol Rep 2023, Cardiovascular safety of psychedelic medicine: current status and future directions. Read 2026-10-22.
- Apud I et al., J Psychoactive Drugs 2023, Ayahuasca, Personality and Acute Psychological Effects in Neo-Shamanic and Religious Settings in Uruguay. Read 2026-10-22.
- US Electronic Code of Federal Regulations, 21 CFR 1308.11 Schedule I. Read 2026-10-22.
- Labate BC et al., Int J Drug Policy 2012, Ayahuasca and the process of regulation in Brazil and internationally: implications and challenges. Read 2026-10-22.